Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array DetectionReportar como inadecuado




Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Analytical Methods in Chemistry - Volume 2015 2015, Article ID 215128, 6 pages -

Research Article

Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt

Laboratory of Pharmaceutical Analysis, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons UMONS, Place du Parc 20, 7000 Mons, Belgium

Received 1 March 2015; Accepted 20 April 2015

Academic Editor: Mohamed Abdel-Rehim

Copyright © 2015 Marwa Fouad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL-min using gradient elution mode. A µSPE solid phase extraction procedure, using Oasis MCX µElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach β = 95% and acceptance limits = ±15% over the ranges 5–250 ng-mL for afatinib and from 5 to 400 ng-mL for ibrutinib in human plasma.





Autor: Marwa Fouad, Maxime Helvenstein, and Bertrand Blankert

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados